Abstract
To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 μg or 100 μg of anti-C1q Ab or isotype Ab. Treatment with 10 μg anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 μg anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 167-176 |
| Number of pages | 10 |
| Journal | Journal of Neuroimmunology |
| Volume | 182 |
| Issue number | 1-2 |
| DOIs | |
| State | Published - Jan 2007 |
Fingerprint
Keywords
- Autoimmunity
- C1q
- Classical complement pathway
- Myasthenia gravis
ASJC Scopus subject areas
- Immunology
- Clinical Neurology
- Immunology and Allergy
- Neurology
Cite this
Pros and cons of treating murine myasthenia gravis with anti-C1q antibody. / Tüzün, Erdem; Li, Jing; Saini, S. Shamsher; Yang, Huan; Christadoss, Premkumar.
In: Journal of Neuroimmunology, Vol. 182, No. 1-2, 01.2007, p. 167-176.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pros and cons of treating murine myasthenia gravis with anti-C1q antibody
AU - Tüzün, Erdem
AU - Li, Jing
AU - Saini, S. Shamsher
AU - Yang, Huan
AU - Christadoss, Premkumar
PY - 2007/1
Y1 - 2007/1
N2 - To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 μg or 100 μg of anti-C1q Ab or isotype Ab. Treatment with 10 μg anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 μg anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy.
AB - To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 μg or 100 μg of anti-C1q Ab or isotype Ab. Treatment with 10 μg anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 μg anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy.
KW - Autoimmunity
KW - C1q
KW - Classical complement pathway
KW - Myasthenia gravis
UR - http://www.scopus.com/inward/record.url?scp=33845884294&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845884294&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2006.10.014
DO - 10.1016/j.jneuroim.2006.10.014
M3 - Article
C2 - 17137637
AN - SCOPUS:33845884294
VL - 182
SP - 167
EP - 176
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
SN - 0165-5728
IS - 1-2
ER -